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CBackground: Personalized medicine technologies can improve indi-
vidual health by delivering the right dose of the right drug to the right
patient at the right time but create challenges in deciding which
technologies offer sufficient value to justify widespread diffusion. Per-
sonalized medicine technologies, however, do not neatly fit into exist-
ing health technology assessment and reimbursement processes.
Objectives: In this article, the Personalized Medicine Special Interest
Group of the International Society for Pharmacoeconomics and
Outcomes Research evaluated key development and reimbursement
considerations from the payer and manufacturer perspectives.
Methods: Five key areas in which health economics and outcomes
research best practices could be developed to improve value assess-
ment, reimbursement, and patient access decisions for personalized O
, Quin
ty fo
viewe
close to either risked destruction of the crew and the ship.edicine have been identified. Results: These areas are as follows: 1
esearch prioritization and early value assessment, 2 best practices for
linical evidence development, 3 best practices for health economic
ssessment, 4 addressing health technology assessment challenges,
nd 5 new incentive and reimbursement approaches for personalized
edicine. Conclusions: Key gaps in health economics and outcomes
esearch best practices, decision standards, and value assessment pro-
esses are also discussed, along with next steps for evolving health
conomics and outcomes research practices in personalizedmedicine.
eywords: diagnostics, health economics and outcomes research, health
echnology assessment, personalized medicine, reimbursement.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Similar to the positioning of Odysseus’ ship between Scylla and Cha-
rybdis,1 personalized medicine technologies are currently caught be-
tween expectations of improving health outcomes and uncertainty
about navigating the rapidly changing regulatory and reimbursement
environment. In an increasingly cost-conscious environment, inwhich
health decision-makers are chargedwithmaking difficult decisions on
the balance of costs and benefits, personalized medicine technologies
* Address correspondence to: Eric Faulkner, Global Market Access
E-mail: Eric.Faulkner@quintiles.com.
1098-3015 – see front matter Copyright © 2012, International Socie
Published by Elsevier Inc.
http://dx.doi.org/10.1016/j.jval.2012.05.006
1 Scylla and Charybdis are twomonsters from Greek mythologyhold the potential to improve health outcomes, provided that value for
money can be demonstrated and data uncertainties addressed.
Personalized medicine has been defined in many ways [1–3]. For
purposes of this article, the Personalized Medicine Special Interest
Group (PM SIG) of the International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) has defined personalized medicine
as the use of genetic or other biomarker information to improve the
safety, effectiveness, and health outcomes of patients via more effi-
ciently targeted risk stratification, prevention, and tailored medica-
tion and treatment-management approaches. Although this article
tiles, 4820 Emperor Blvd., Durham, NC 13979.
r Pharmacoeconomics and Outcomes Research (ISPOR).
d as virtually impossible for ships to pass between, as getting too
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phasis is primarily on pharmacogenomic or pharmacogenetic (here-
after labeled PGx) applications, in which use of a companion diag-
nostic informs selection or use of specific medicinal products.
Key challenges associated with PGx include translation of
knowledge into clinical practice, lack of best practices for value
assessment, and integration into evolving health care delivery
models [4–6]. Potential benefits have also been characterized to
nclude the following [1,7–10]:
● Increased certainty about diagnosis andmechanism of disease
● Improved estimation of patients’ risks of later outcomes (e.g.,
prognosis), which could influence treatment management de-
cisions
● Better prediction of response to therapy or drug metabolism
rates or a reduced potential for adverse events
● Reduced wastage of health resources associated with treating
nonresponders
● Improvement in the quality and cost-effectiveness of patient-
tailored treatment versus empirical approaches to prescribing
Assessment of the added value of PGx approaches is complex and
depends onmany factors including the safety and performance of
the diagnostic or treatment, biomarker prevalence, utility of the
test for informing patient management, and the comparative ef-
fectiveness of the test-treatment strategy versus standard of care
(SOC). As with any emerging technology scenario, clarifying areas
of uncertainty and moving toward standard regulatory and reim-
bursement practices will facilitate the broader adoption of PGx
into clinical practice [11].
Two of the stakeholder groups with significant influence on
innovation and uptake of PGx technologies are the payer and the
technologymanufacturer (including both diagnostic and pharma-
ceutical developers). Payers include a wide variety of governmen-
tal and private organizations thatmanage reimbursement and ac-
cess to patient care. They vary in size, scope, and the extent to
which they manage or commission care. Some payers enforce
strict coverage rules, while others allow clinicians a great deal of
latitude to determine appropriate care for each patient.While reg-
ulators, physicians, and patients also influence the uptake of PGx,
this article characterizes key issues associated with PGx from the
payer and manufacturer perspectives, identifies key challenges
facing them, and considers the role of health economics and out-
comes research (HEOR) methods in addressing these challenges.
Methods
The ISPORBoard ofDirectors approved the formation of the PMSIG
to develop a document on HEOR practices/considerations for di-
agnostics and personalized medicine in late 2009. Researchers
experienced in this field and working in academia, research orga-
nizations, the pharmaceutical industry, or US or European govern-
ments were invited to join the Leadership Committee of the PM
SIG. The PM SIG held several discussion sessions and conducted a
review of the peer-reviewed literature in PubMed and The Co-
chrane Library and available gray literature to identify key issues
related to HEOR and reimbursement of diagnostics and personal-
ized medicine. The issues relevant to the article were presented
for comment in 2010 at both the ISPOR 15th Annual International
Meeting (held in Atlanta, GA) and the 13th Annual European Con-
gress (held in Prague, Czech Republic). Drafts of the article were
also sent for comment to the global PM SIG review committee, a
leadership committee of 60 US commercial payers of the National
Association of Managed Care Physicians, and the international
Advanced Medical Technology Association.Issues in Technology Assessment and Payer
Decision Making
Choosing the best medicine and its correct dose for the individual
patient remains a largely empirical process; clinicians prescribe
treatment, observe the outcome, and adjust drugs and doses ac-
cordingly. It has long been understood that some patients respond
better to certain therapies than do others, but it is difficult to know
a priori which individuals will respond to a particular treatment.
For payers, this uncertainty results in inefficiencies in selecting
treatment, managing cost, and optimizing patient outcomes.
Payers in countries with formal health technology assessment
(HTA) programs are increasingly likely to deny or severely restrict
reimbursement of therapies when the clinical and/or economic
value proposition for the broader patient populations is unfavor-
able, unclear, or unexceptional [12–16], as they seek to limit cov-
erage of such therapies to subpopulations most likely to benefit.
The potential of PGx to effectively target responders, improve out-
comes, and reduce costs appeals to payers [4,17–19].
In principle, payers benefit from the availability of companion
diagnostics that accurately identify responders, reduce the num-
ber needed to treat, and thereby improve the efficient use of scarce
resources. Payersmay also support tests focusing on safety—such
as the test for the JC virus to identify immunosuppressed patients
at risk for potentially fatal progressive multifocal leukoencepha-
lopathy—if, by increasing the number needed to harm, testing is
cost-effective for risk identification [20]. Payers may also consider
the societal consequences of test-and-treat strategies and system
integration challenges. Although payers recognize the potential
advantages of PGx, they are also cautious regarding the potential
downsides of this approach.
Emerging PGx technologies often involve gene-based and other
molecular tests. Currently, single-marker diagnostics often have
an acquisition cost of less thanUS $400 per patient. From the payer
perspective, it is often considered a reasonable investment to de-
termine whether a medicine with annual costs of $20,000 to
$100,000 is likely to benefit a particular individual. The rapid inte-
gration of KRAS, epidermal growth factor receptor (EGFR), and BRAF
mutation testing into clinical guidelines for cancer patients receiv-
ing cetuximab, erlotinib, and vemurafenib, respectively, provides
key examples of rapid PGx uptake by payers across major health
care markets. Pharmaceuticals that have launched with the nec-
essary tools to locate responders have generally gained payer ac-
ceptance, for example, trastuzumab and imatinib [21–24]. The ini-
tial market failure and later reemergence of gefitinib with a
companion diagnostic (EGFR) also illustrates payer willingness to
accept scenarios for which the responder population is clearly
identified [25–27]. Examples of marketed PGx tests and their in-
tended use are highlighted in Table 1.
However, PGx scenarios are not always a guarantee of payer ac-
ceptance [28–30]. In a recent review of cost-effectiveness studies on
PGx tests, Paci and Ibaretta [31] reported that 27%of studied testshad
unfavorable or equivocal cost-effectiveness compared with SOC (al-
though almost three-quarter of these were deemed cost-effective
compared with SOC). Some diagnostics developed separately from
the companionmedicine (e.g., testing to informwarfarin dosing and
CYP2C19 testing to identify clopidogrel [Plavix] responders) have not
achieved broad payer acceptance because evidence of the links be-
tween testing, treatment, and health outcomes is not well estab-
lished [32,33]. Payers must also consider unmet need and ethical is-
sues in evaluating PGx,where a subpopulation-targeted treatment is
identified but no effective alternatives exist.
Cost-effectiveness estimates for recent pharmaceutical-diagnos-
tic combinations have been highly variable among major HTAmar-
kets, suggesting thatmethods for incorporating test information into
economic evaluations are inconsistent. One example is EGFR testing
before gefitinib trial. Themanufacturer submitted cost-effectiveness
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1164 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 1 6 2 – 1 1 7 1estimates of £23,615 per quality-adjusted life-year (QALY) and the
National Institute for Health and Clinical Excellence estimated cost
per QALY at £35,700 while the Scottish Medicines consortium esti-
mated £154,022 per QALY [25,34,35]. Clearly, best practices for mod-
eling economic outcomes of PGx strategies are needed, including
how to incorporate diagnostic characteristics (e.g., test performance
andreceiveroperatingcharacteristic curves) into sensitivityanalyses
and value assessments and address gaps or uncertainties in infor-
mation related to the diagnostic test.
Our review identified many questions specific to PGx and/or
diagnostics scenarios that payers and HTA agencies should con-
sider (Table 2). Such questions have significant implications for
EOR and value assessment for PGx and underscore the need for
dapted methodological approaches for diagnostics. Aside from
merging regulatory requirements [36], methodological ap-
proaches fall into two key dimensions: 1 framework for HTA and
decision-making criteria and 2 level and nature of evidence that is
required for HTA. At present, differingmethodological approaches
and experience with handling PGx may result in highly variable
patient access decisions.
Payers also face broader challenges to decisionmaking regard-
Table 1 – Payer and health technology assessor
questions to determine the value of test-treatment
combinations.
Payer and HTA agency considerations
y What is the accuracy of the test? To what extent are
responders overidentified (false positives) or missed (false
negatives) by the test?
y Are the test results actionable? Does the result(s) lead to
changes in clinical practice? Will physicians use the test to
inform treatment selection or ignore results? What potential
harms are associated with the test?
y Is test interpretation clear? Are test results binary (i.e., yes/no)
or is there an intermediate range of test results that may
complicate physician acceptance of the test and enforcement
of coverage policies that limit access to responders?
y Are the test results actionable? Has a dosing algorithm (for
instance) been developed, validated, and tested for
effectiveness?
y What is the clinical utility of the test (i.e., does use of the test
improve health outcomes)?
y Has an RCT been performed of a test-and-treat strategy versus
standard of care?
y How many tests must be paid for before one treatable patient
or adverse event is identified? What is the number needed to
test, the number needed to treat, and the number needed to
harm?
y How much more effective is the treatment in the responder
population compared with standard-of-care alternatives?
y What is the proper comparison strategy for a PGx test and/or
medicine if others do not exist for that indication?
y What is the budget impact of avoiding resource wastage by
treating nonresponders with alternatives?
y Based on the cost of the test and the associated treatment,
what proportion of responders must be identified to make the
PGx scenario clinically beneficial and cost-effective?
y Should all patients receive the test before accessing alternative
medicines in the same position (e.g., first-line vs. second-line)
or formulary tier? How would this influence appropriate
access?
y How do we handle the multiple diagnostic tests that may
emerge after launch of a diagnostics-driven medicine? What
are the implications for their variable test performance on
patient outcomes and cost-effectiveness?
HTA, health technology assessment; PGx, pharmacogenomic/phar-
macogenetic; RCT, randomized controlled trial.ing PGx interventions. Key issues include uncertainties aroundevidence assessment, gaps in the evidence supporting clinical
utility and cost-effectiveness of diagnostics, when modeling is
sufficient/possible versus when additional clinical evidence is
essential to address uncertainties, applicability of risk-sharing
agreements based on test results, variability in evidence support-
ing laboratory-developed versus regulatory-approved tests, insuf-
ficient communication between authorities evaluating tests and
treatments, difficulty tracking diagnostic utilization, and lack of
infrastructure or mechanisms to support or fund diagnostic test-
ing [1,8,37–39]. In the case of clinical utility, for example, inconsis-
tent definitions and availability of evidence and uncertainties re-
garding assumptions can compromise decision making [40].
owever, payer recognition that numerous PGx technologies are
n the pipeline has prompted HTA agencies and payers in some
arkets (e.g., Australia, Canada, France, the United Kingdom, and
he United States) to consider implementation of more explicit
ecision criteria/guidelines, policies, and infrastructure.
Issues Associated with Development of
Pharmacogenomic Diagnostics and Treatments
Retooling pharmaceutical business models around targeted thera-
pies has affected many aspects of the pharmaceutical development
process, from research and development to reimbursement and
market access. More than 50% of biopharmaceutical manufacturers
have integrated PGx into development programs to better support
product differentiation andmarket access potential [41,42]. As a con-
equence, patient subpopulations identified by PGxmaybe too small
o be profitable. To balance smaller population sizes and growing
evelopment costs, pharmaceutical manufacturers have increased
ricing for targeted therapies over the past 15 years [43,44]. Rising
reatment prices have in turn spurred heavier payer scrutiny [45,46].
Many new PGx diagnostics are also more costly than historical
nd routine tests, often ranging from the low hundreds to the
housands for a few emerging multimarker tests (e.g., Oncotype
X, AlloMap, ChemoFX, andMammaPrint). At present, only a small
number of PGx tests have become established in clinical guidelines
(e.g., tests for HER2 and KRAS), although many others are routinely
used in practice (see Table 2). As the availability and cost of diagnos-
tics have increased, payer emphasis on diagnostics has grown in
tandem, pushing test manufacturers toward value demonstration
approaches similar to those used for pharmaceuticals [9,47].
Differing business incentive structures between diagnostic and
treatment manufacturers also currently complicate development
and collaboration. Key challenges include markedly different reim-
bursement and market incentive structures, resources to support
evidence development, and intellectual property protections
[37,40,48]. The potential profitability of PGx may be influenced by
factors such as budget constraints, rigor of HTA processes, reimburse-
ment coding, population demographics, and growth and demand for
newhealth services. In addition,many pharmaceuticalmanufacturers
are still in the early stages of assessing the commercial implications of
codevelopment and evolving infrastructure to support PGx.
At present, many uncertainties around PGx approaches remain
from both the test and treatment manufacturers’ perspective (Table
3). These uncertainties require manufacturers to consider the HEOR
and commercial implications of biomarkers at every stage of the
pharmaceutical life cycle. Both methodological and practical busi-
ness challenges highlighted in Table 3 limit the degree to which di-
agnostics manufacturers can pursue evidence development initia-
tives similar to therapeutics. Uncertainties regarding clinical and
economic evidence requirements, limited intellectual property pro-
tection, and lack of value-based payment remain the key hurdles to
diagnostic commercialization. In addition, it can also be substan-
tially more difficult to demonstrate the clinical utility of stand-alone
tests, given currentmarket incentives and lack of clarity on decision
requirements.While codevelopment scenarios enable thediagnostic
1165V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 1 6 2 – 1 1 7 1to establish a closer correlation between test use and health out-
comes, questions remain regarding appropriate economic assess-
ment methods. Some regulatory authorities, such as the Food and
Drug Administration, have worked toward clarifying expectations
around codevelopment scenarios [36]. Until these factors are ad-
dressed, they remain pivotal limitations to companion diagnostic
innovation.
In addition to diagnostic considerations, pharmaceutical man-
ufacturers must consider a host of new issues specific to codevel-
opment (see Table 3). From the manufacturer’s perspective, deci-
sions to pursue PGx development versus conventional “treat-all”
approaches are complex and depend on many factors including
patient population size, pharmaceutical cost (and patent status)
and volume trade-offs, degree of payer management of the target
indication, and potential for value differentiation [49]. Key uncer-
Table 2 – Examples of commercially available PGx tests an
Diagnostic Company
Diagnostics for selecting patients
for a therapy or informing
therapy use/modification
AlloMap XDx
AmpliChip CYP 450 Roche/Affymetrix
c-Kit pharmDx Dako/Novartis
cobas 4800 BRAF V600 Mutation
Test
Roche
EGFR Dako, Zymed, Invitrogen, DxS/
Qiagen/Merck-Serono
HER2 neu Dako, Abbott, Ikonisys, Kreatech
Dx, Oncor, Invitrogen/Roche
KRAS DxS, Qiagen, Transgenomic/
Merck-Serono
PGxPredict: CLOZAPINE PGxHealth (clinical data)/Novart
PGxPredict: Rituximab PGxHealth (clinical data)/Novart
Therascreen EGFR RGQ PCR Kit Qiagen/Astra-Zeneca
Qiagen/Boehringer Ingelheim
Trofile Monogram/Pfizer
Vysis ALK Break Apart FISH
Probe Kit
Abbott/Pfizer
Diagnostics to determine risk or
prognosis
BRAC Analysis Myriad
ChemoFx Precision Therapeutics
Familion PGxHealth (clinical data)
Femtelle American Diagnostica (Sekisui
group)
MammaPrint Agendia (NL)
Mammastrat Applied Genomics, Clarient
Oncotype Dx Breast Cancer Genomic Health
Oncotype Dx Colon Cancer Genomic Health
Phenosense GT Monogram
PreGen-Plus Exact Sciences
Prostate Px Aureon Biosciences
Dx, diagnosis; EGFR, epidermal growth factor receptor; FISH, fluores
oncogene homolog; PCR, polymerase chain reaction; Rx, treatment.tainties related to HEOR and market access include integration ofPGx into early “go/no go” decision models, best practices for inte-
grating testing into clinical trials and economic models, implica-
tions of testing on reimbursement and uptake, PGx value commu-
nication, and uncertainty regarding test funding and the need for
risk-sharing arrangements. Despite the availability of applicable
clinical and economic methodologies for the assessment of med-
icines, significant room exists for the refinement of HEOR ap-
proaches tailored to address PGx issues.
How HEOR Can Help Improve Decision Making
Regarding Pharmacogenomics
Our SIG identified five key opportunities for the use of HEOR ap-
proaches to improve decisions regarding the advancement of PGx.
ir intended use.
Intended use
o identify heart transplant recipients with stable allograft function
to inform patient treatment decisions
o identify CYP variations to individualizing treatment dose for
certain drugs
o identify patients with gastrointestinal stromal tumors eligible for
treatment with Gleevec/Glivece
o detect EGFR in colorectal cancer for Erbitux or Vectibix Rx
candidates
o detect EGFR in colorectal cancer for Erbitux or Vectibix Rx
candidates
o detect HER2 in breast cancer for Herceptin Rx candidates
o detect KRAS in colorectal cancer for Erbitux or Vectibix Rx
candidates
o ascertain the risk of clozapine-induced agranulocytosis
(treatment of schizophrenia)
o select patients with non-Hodgkin’s lymphoma for rituximab
(Rituxan/MabThera) Rx
o detect EGFR mutations to select patients with non–small-cell
lung cancer (NSCLC) for the tyrosine kinase inhibitor gefitinib
(Iressa) or afatinib (TomTovok)
o test for HIV-1 coreceptor tropism; companion test to maraviroc
(Selzentry, or Celsentri outside the United States)
o identify the expression of an abnormal anaplastic lymphoma
kinase gene for selecting patients with locally advanced or
metastatic NSCLC for treatment with crizotinib (Xalkori)
o detect carriers of BRCA gene mutations, at risk of breast and
ovarian cancer
o determine chemotherapy resistance
o diagnose of 9 different familial cardiac syndromes
or prognosis of patients with breast cancer, to select patients most
likely to benefit from chemotherapy
o assess a breast cancer patient’s risk for metastasis
o classify individual patients as having the risk of breast cancer
recurrence
o predict the likelihood of breast cancer recurrence
o predict the likelihood of colon cancer recurrence
o check resistance to drugs for HIV
o screen for colorectal cancer
o calculate prostate cancer patient’s probability of disease
progression
in situ hybridization; KRAS (or v-Ki-ras2), kirsten rat sarcoma virald the
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1166 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 1 6 2 – 1 1 7 1could be further developed or defined. These opportunities span
the current continuum from early to later-stage decisions with
emphasis on addressing key gaps associated with development,
evaluation, and reimbursement of PGx technologies.
Informing research prioritization and early value assessment
Two related approaches used in HEOR can inform the assessment
of the potential value of PGx at an early stage and prioritization of
further research: 1 early-stage decisionmodeling of potential cost-
effectiveness and 2 formal value-of-information (VOI) analyses
[50,51]. The foundation of many cost-effectiveness (and cost anal-
yses, which we subsequently label as cost-effectiveness analyses
because they have the same theoretical framework) is the con-
struction of a decision-analytic model to estimate the projected or
actual cost-effectiveness (or cost utility) of a new personalized
medicine. These models can vary in complexity from a simple
Table 3 – Typical diagnostic and pharmaceutical manufact
approaches.
Diagnostic developer considerations
Development considerations
y At what time in the pharmaceutical life cycle should test
development begin?
y Is
d
s
y What relationships with pharmaceutical manufacturers are
feasible?
y Is
c
y What intellectual property protection is available? y W
v
y Will evidence development efforts pave the way for “fast
follower” tests with lower hurdles to market?
y Would a rule-in or rule-out test be most
y important for payer and physician acceptance?
Evidence and HTA considerations
y What minimum test performance will be required to support
the test?
y W
p
y What percentage of false positives and false negatives will
jeopardize payer and physician acceptance of the test?
y H
a
y What evidence is minimally necessary to demonstrate
clinical utility?
y W
b
d
y What is the minimum evidence necessary to support
reimbursement given the
y limited potential for value-based pricing? y W
te
y How will HTA agencies and payers define clinical utility for
the test application?
y H
li
y What economic data, aside from the cost of the test and
budget impact, are essential for test acceptance?
y A
e
y What approaches to modeling clinical utility and cost-
effectiveness will be acceptable to HTA agencies and payers
(if any)?
Commercial considerations
y Are there barriers to physician adoption of the test (e.g., lack
of familiarity, invasive testing method)?
y W
p
y W
y Would the test solve a substantive decision problem or
change patient management?
y c
y What is the commercial potential of the test if the medicine
fails?
y U
m
y How can we increase the likelihood that decision makers will
support the use of our specific test versus alternative tests?
y W
y What potential is there for value-based pricing of the test (if
any)?
y Is
a
HTA, health technology assessment; PGx, pharmacogenomic/pharmcalculating tool to a simulation model with hundreds of input pa- erameters. These models can also incorporate the extent of uncer-
tainty about specific parameters and explore the potential impact
of uncertainties through sensitivity analyses. A projection of the
cost-effectiveness of a new personalized medicine could be used
to informmanufacturer “go/no go” decisions, particularly if payer
and physician acceptance criteria are understood and included in
the model. Such approaches are most likely to be valuable in the
private sector, where value or return on investment is measured
as revenues and profits [52]. From a societal perspective, health
enefits may sometimes be approximated on the basis of pro-
ected revenue (i.e., market price as a proxy for societal benefit).
his assumption, however,may not hold if diagnostics reimburse-
ent is cost-based and not value-based, or if medicine prices and
eimbursement are not closely linked to value delivered [48].
HEOR researchers are increasingly using VOI analyses to study
he value of research to reduce uncertainties surrounding the ben-
questions to determine the viability of pursuing PGx
Medicine manufacturer considerations
marker required for success of the new pharmaceutical in
pment? Are single-marker or multimarker tests more likely to be
ted by payers?
orrelation between the biomarker and the treatment outcome
r well understood?
evel of test performance (i.e., sensitivity, specificity, and predictive
is required for a test-treatment combination to be viable?
s the optimal percentage of treatment responders required for
ian and payer acceptance?
ill HTA agencies and payers define clinical utility for the test
tion?
linical and economic evidence is required to support the
rker test under a codevelopment scenario, and what type of study
is best suited to provide such evidence?
omparators are most applicable to support reimbursement of the
eatment combination?
o differing HTA and reimbursement processes impact the
ood of test and treatment acceptance?
t point does the cost of the test make demonstration of cost-
veness unlikely?
re the implications of including the biomarker in the
aceutical label?
biomarker strategy help or hinder
ercialization? If so, how?
what circumstances will payers accept higher pricing given smaller
t sizes associated with PGx approaches?
hould pay for testing—the payer or the manufacturer?
e a role for risk-sharing agreements to tackle uncertainties around
nalized medicine?
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reducing uncertainty about intervention use. VOI analysis can be
conducted on the basis of information from preliminary studies,
cost-effectiveness models, and informed expert opinion. VOI anal-
yses may be most valuable in the public sector, where quantifying
the value of conducting a specific study ismore challenging because
the information generated is not directly linked to revenues [57].
Early-stage cost-effectiveness analyses models and VOI analy-
ses may be particularly useful in personalized medicine. These
approaches can help test manufacturers to prioritize investment
decisions, including whether or not to generate more evidence.
The same applies to pharmaceutical manufacturers whomust de-
cide whether to develop a companion diagnostic that identifies a
restricted stratum of patients. These analyses can project the im-
pact of testing on overall efficacy and safety and can also suggest
the commercial impact in terms of price, reimbursement, and
budget impact—as well as the societal benefits.
Identification of best practices for clinical evidence
development involving PGx
Multiple factors currently complicate the development of clinical
evidence supporting diagnostics and PGx, including 1 challenges
in early determination of the clinical value of biomarkers; 2 incon-
sistent understanding or application of diagnostic terminology; 3
variability in diagnostic regulatory requirements; 4 limited incen-
tives to develop “ideal” or direct evidence characterizing test val-
ue; and 5 lack of clear and consistent standards for study design or
HTA, payer, and provider acceptance [1,58].
Early diagnostic association studies are not often developed to
answer downstream decision-maker questions regarding clinical
and economic value. Further, the process of regulatory evaluation
of tests is more proportionally focused on ensuring standardized
processes for testing and test performance than efficacy and
safety (unless codeveloped). Some tests may also be subject to
stringent evaluation by regulatory bodies, while other tests may
emerge as laboratory-developed tests that are subject to very dif-
ferent evidence requirements. These factors often complicate
downstream value assessment by HTA agencies, payers, and pro-
viders [59].
Whereas therapeutic study designs are generally well agreed
upon in terms of acceptability for HTA and reimbursement deci-
sionmaking, this is not the case with diagnostics and PGx studies.
Lack of sufficient evidence linking test use to patientmanagement
and health outcomes remains a fundamental challenge for reim-
bursement decisions [37]. There is significant need for identifica-
ion incentives and harmonization of clinical best practices that
eflect specific characteristics of diagnostics and PGx.
Some alternative evaluation frameworks for diagnostics have
een proposed in the United States, including by the American
ociety of Clinical Oncology [60] and the National Institutes of
Health [61]. No single approach, however, has yet emerged as stan-
dard. These frameworks provide insights into alternative study
design approaches that may better address diagnostics evidence
questions (e.g., use of retrospective and prospective observational
studies). Future HEOR may consider the advantages and limita-
tions of such novel frameworks, as well as differences between
stand-alone diagnostics and companion diagnostics validated in
the context of phase 3 clinical trials.
Clinical evidence standards and best-practices development
for PGx should strive to balance the following: 1 robustness: to ad-
dress HTA and payer questions regarding diagnostic and PGx
value, 2 feasibility: given current market incentives/limitations,
and 3 flexibility: including approaches for addressing uncertainties
and evidence gaps via alternative study designs or data-collection
approaches. Evolving longitudinal data-collection approaches
(e.g., real-world data, patientmedical records, or registries) should
also be explored as alternatives to addressing gaps in clinical evi-dence. The implications of time to obtain test results and test
reliability should also be considered in the assessment of clinical
value. Improving consensus and consistency around evidence de-
velopment for diagnostics and PGx would in turn support evolu-
tion of improved economic assessment in this evolving field.
Identification of best practices for economic modeling
involving PGx
There are well-established scientific standards and key principles
for performing economic evaluation and HTA [62–64]. Because ev-
idence from many different types of studies (e.g., test perfor-
mance, treatment safety and efficacy, quality of life, and costs)
must be combined in PGx decision making, decision-analytic
modeling may be used to guide such decisions [65]. The special
spects of PGx, however, are not explicitly addressed in the exist-
ng guidelines.
As decision-makers and payers show an increased demand for
ost-effectiveness data related to test-treatment approaches,
here is need for identifying best practices for economic modeling
n this field (Fig. 1). This is the case both for codevelopment situa-
tions and when the diagnostic is developed as a stand-alone test.
In regard to the latter, approaches must address evidence gaps in
a manner that is both acceptable to payers and feasible for test
manufacturers. Fundamental questions such as how to handle
inclusion of the diagnostic inmodels; characterization of differen-
tial budget impact versus SOC; standards for establishing links
between test use, patientmanagement, and outcomes; the impact
of uncertainty on model outcomes; and whether the QALY is the
bestmetric for diagnostics and PGx remain to be answered [50,66–
68]. Model structure, data used as model inputs, and model vali-
dation approaches are the three areas in which best practices
must be established [69].
Models involving PGx must reflect “real-life” decision making
and use. In PGx, the choice to be made is no longer between a new
medicine “B” and an existing medicine “A,” but between a “treat-
all” strategy and a “test-and-treat” strategy. A straightforwardway
to model this may be to start from the real prevalence of the bio-
marker that is associated with increased treatment response (or
reduced adverse events), as the gene-expression test example in
Figure 2 depicts.
As for data input, the rate of false positives and false negatives
should be taken into account in the model, as well as conse-
Fig. 1 – Potential risks and benefits of pharmacogenomics
from the payer perspective. Source: Health Outcomes
Strategies (2010).quences of a positive test or a negative test. If evidence on out-
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1168 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 1 6 2 – 1 1 7 1comes is not yet available, the relationship between test results,
medical management, and patient outcomes may be assembled
from the literature to infer clinical utility. This would be similar to
traditional models that translate efficacy into effectiveness. This
is particularly true for stand-alone PGx diagnostics that do not
follow a codevelopment pathway to yield direct evidence linking
test use to treatment outcomes. Extrapolating clinical utility may
also be complex for testing scenarios involving multiple biomark-
ers (e.g., arrays and multiplex tests) that are beginning to emerge
in clinical practice, as well as in those cases in which there is a
nonbinary outcome of the test. In the latter case, modelers have to
consider multiple cutoff points and evaluate together with expert
clinicians the medical management and/or further diagnostic
practice resulting from the test result [69].
Developing models appropriate for PGx may involve 1 an in-
creased role for expert elicitationmethods to populatemodels and
address gaps and 2 increased emphasis on parameter and struc-
tural sensitivity analysis to test key assumptions and support de-
cision making. It is also crucial that such models consider ap-
proaches to reflect face validity (i.e., the results make sense) and
external validity (i.e., the results are generalizable and consistent
with real-life data). This is because in the absence of direct clinical
evidence, payer scrutiny of modeling assumptions and outcomes
will be heightened.
Addressing HTA challenges for PGx
Although it is possible to use current HTA frameworks to evaluate
PGx technologies, there is no evidence to support whether this is
either appropriate, in terms of methodological decision frame-
works, or feasible, in terms of data requirements. Commonly ac-
cepted standards, both within and across different jurisdictions,
on how to evaluate diagnostics and test-treatment combinations
have not yet been transparently established or agreed upon by
leading HTA organizations and payers [11,70,71].
To help ensure that only clinically and economically valuable
Gx technologies are used in practice, payers need to develop ex-
licit HTA practices, decision criteria, and utilization metrics [72].
everal organizations such as the European PersonalizedMedicine
Fig. 2 – Example of decision tree for modeling economic out
supportive care. Source: Health Outcomes Strategies (2010).iagnostics Association, the EU Framework VII program, the Eval-ation of Genomic Applications in Practice and Prevention of the
S Centers for Disease Control and Prevention, and the Agency for
ealthcare Research and Quality are working to explore eviden-
iary criteria for diagnostics and PGx applications. Explicit require-
ents for health outcomes and economic evidence to support di-
gnostics are slowly beginning to evolve. Initiatives such as the
echnology Appraisal and Diagnostics Assessment Programme of
he National Institute for Health and Clinical Excellence in the
nited Kingdom and draft guidance on assessment of codepen-
ent pharmaceutical-diagnostic technologies released by the
edical Services Advisory Committee and the Pharmaceutical
enefits Advisory Committee in Australia are poised to advance
conomic standards for diagnostics and test-treatment combina-
ions [73,74].
Development of PGX decision analysis frameworks and sup-
ort tools involving being useful to a broader array of stakeholder
ecision-makers (e.g., providers and laboratory directors) may
lso support appropriate adoption and use. Methods for address-
ng emerging issues such as comparative effectiveness and “real-
orld” data associated with PGx and diagnostics would also in-
orm the development of necessary best practices [75–77].
As explicit criteria for HTA of diagnostics and PGx evolve, it will
e important that such criteria take into account 1 special eviden-
iary considerations that differ from traditional pharmaceutical/
herapeutic scenarios; 2 incentive structure limitations; and 3 dif-
erent evidence considerations by testing application (e.g.,
creening, treatment selection, and monitoring) [9,68,71]. Until
ealth system incentive structures that better support the devel-
pment of diagnostic evidence evolve, clinical and economic
ethodologies that can help address existing evidence gaps are
eeded [78]. Recent HTA evaluations, however, have begun to in-
corporate value considerations specific to diagnostics and PGx,
including test performance and the role of diagnostic information
in decision making and improved treatment outcomes [79–81].
Addressing incentive structures and reimbursement for PGx
Various options for companion diagnostic value creation and cap-
ture have been analyzed by using a variety of possible scenarios
s of a novel medicine-diagnostic combination. BSC, bestcomeabout the sequence of their development and pricing flexibility
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based, flexible pricing” for both diagnostics and therapeutics could
strengthen economic incentives for the development of compan-
ion diagnostics and attribution among relevant PGx technologies
and stakeholders. Several issues specific to value characterization
and HEOR are highlighted as follows.
PGx tests may vary greatly in price as well as in clinical utility.
Application of value assumptions to PGx can be challenging be-
cause 1 not all tests for a specific biomarker are functionally equiv-
alent or well characterized and 2 multiple test types for a specific
biomarker may be available with different levels of supporting
evidence. As the field expands, payers will need to find a way to
encourage appropriate investigation of the usefulness of PGx
while avoiding indiscriminate coverage of tests that may provide
limited evidence of value. In addition to evolving payer and HTA
processes, some third-party vendors in the United States such as
Medco and CVS Caremark are developing processes for managing
pharmaceutical access by requiring testing for proven biomarkers.
These trendsmay be supported by adaptiveHEOR approaches that
link available evidence to appropriate decision frameworks with
patient safeguards.
Unlike pharmaceuticals, diagnostics have limited “pricing lat-
itude” and are not typically subject to value-based payment, irre-
spective of their value to support decision making [9]. Reimburse-
ment of diagnostics is cost-based in most countries and typically
results in low prices. There is currently limited ability for the di-
agnostic manufacturer to gain a return on research and develop-
ment by capturing some of the value created by a test-pharmaceu-
tical combination. This has in some recent PGx examples led to
pharmaceutical company funding the development of the com-
panion diagnostic test itself. To date, the value associated with
PGx scenarios (e.g., HER2 and trastuzumab, KRAS and panitu-
umab, and EGFR and gefitinib) has predominantly been captured
n the price of the pharmaceutical, creating a dilemma for test
evelopers. Only recently launched multimarker molecular diag-
ostics (e.g., GenomicHealth’s OncotypeDX) have achieved value-
ased pricing via clarifying the likely value of treatment for a par-
icular patient and saving the costs of medicines to payers.
A value-based pricing mechanism will be of even greater im-
ortance to PGx test manufacturers associated with generic med-
cines, such as warfarin, tamoxifen, and carbamazepine. In addi-
ion, the scope of patient co-payment and the influence of
illingness to pay has at present received limited emphasis in the
ontext of personalized medicine [82].
Nonspecific coding/tariff descriptions that are focusedmore on
escribing the process associated with testing (e.g., polymerase
hain reaction and fluorescence in situ hybridization) makes it
xtremely difficult to track outcomes associated with diagnostics.
his nonspecific coding frequently requires use of multiple codes
i.e., “code stacking”) to cover steps involved in certain molecular
esting regimes. This “black box” problem, where payers have lim-
ted ability to understandwhat specific test was conducted,makes
t difficult for payers to characterize value andmoderate access to
edicines. Some groups, such as the American Medical Associa-
ion, have under way preliminary work on strategies to revamp
his nonspecific coding challenge [83].
Another important issue is “Who pays for the companion
iagnostic?” and/or “Where will the funding come from to cover
he cost of testing?” Recent market access scenarios in Europe
nd Australia for PGx medicines that require KRAS and EGFR
esting have involved situations where the pharmaceutical
anufacturer will pay for testing (either short- or longer-term)
s a condition of medicine market access. While this may ad-
ress some short-term financial pressures, it complicates value
haracterization for PGx. Implications of this trend will be im-
ortant to consider for stand-alone diagnostics as such cost-
haring approaches evolve.It is also important to recognize the limitations of intellectual
roperty protection as a barrier to market entry in the diagnostics
rena. Value-based prices will be competed down if test entrants
an copy the innovators’ approach without having to make the
ame investment. Low prices and poor intellectual property make
t unrealistic for most diagnostic manufacturers to invest in
ideal” studies to demonstrate clinical utility. Currently, therefore,
he PGx market is highly dependent on pharmaceutical manufac-
urers to demonstrate the value of a diagnostic-medicine combi-
ation. New incentivemodels and/or development of HTAmodels
hat acknowledge these issues will be necessary to optimally ad-
ance PGx.
Conclusions
This article presents an overview of key issues with PGx applica-
tions from the payer and manufacturer perspective, with an em-
phasis on identifying areas for the development of best practices
in personalized medicine. The five broad areas for the develop-
ment of HEOR approaches specific to PGx (and diagnostics) high-
lighted here reflect core areas of focus for evolving appropriate
best practices and standards, including for clinical and economic
evidence development, HTA, reimbursement, and market access
for these rapidly evolving technologies.
Although best practices and key principles exist for HEOR and
HTA in general, there are no commonly accepted standards for
applying these methods to PGx strategies. Development of busi-
ness incentives and clarification of reimbursement process and
payment policy uncertainties represent opportunities for the evo-
lution of HEOR and decision approaches for PGx. Other challenges,
such as intellectual property protections, health system infra-
structure, and health care reform, also complicate the evolution of
best practices and adaptive approaches to addressing PGx.
Many important issues associated with PGx assessment high-
lighted in this article suggest refinement and adaptation of current
HEOR approaches to inform reimbursement and access decisions.
This should include evaluation methods that anticipate current
evidence limitations. Key areas of refinement include research-
prioritization, processes to support business decisions on PGx, re-
evaluation of incentive and reimbursement mechanisms, clarifi-
cation of evidence requirements, and development of decision-
analyticmodeling approaches that are appropriate for both payers
and manufacturers.
While some progress has been made, more research is needed
to decide on best practices for PGx, starting from a critical review
of current evidence used in HTA decisions for PGx and identifica-
tion of gaps and challenges relevant to best-practice formation.
ISPOR is actively working on the development of adaptive HEOR
approaches and standards relevant to the rapidly evolving field of
personalized medicine to help address best practices, standards
development, and transparent and consistent health decision
making.
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